NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=126945&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com […]

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=126956&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/caribou-biosciences-inc-lawsuit-submission-form?prid=126954&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=126951&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Grocery Outlet Holding Corp. (NASDAQ:GO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/grocery-outlet-holding-corp-lawsuit-submission-form?prid=126948&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=126943&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

TALLINN, Estonia, Feb. 03, 2025 (GLOBE NEWSWIRE) — Astrad, a global leader in digital advertising, announces significant enhancements to its Account-Based Marketing (ABM) platform, introducing advanced deterministic data capabilities and sophisticated intent-based targeting features. These upgrades enable B2B marketers to identify and engage high-value accounts with impressive precision. The enhanced platform is based on 100%

FARMINGDALE, N.Y., Feb. 03, 2025 (GLOBE NEWSWIRE) — MMP Capital, a private commercial lender specializing in healthcare finance, as well as financing across multiple verticals, proudly announces a record-setting performance in December 2024 and Q4 2024. With total originations hitting USD 55.6 million for December. The company has gone above and beyond its previous monthly

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=126942&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your ESSA Pharma Inc. (NASDAQ:EPIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/essa-pharma-inc-lawsuit-submission-form?prid=126941&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or